Literature DB >> 24029545

Depression in glioma: a primer for clinicians and researchers.

Alasdair G Rooney1, Paul D Brown, Jacob C Reijneveld, Robin Grant.   

Abstract

Depression is one of the leading causes of global disability, and a considerable hidden morbidity among patients with glioma. In this narrative review, we summarise what is currently known about depression in glioma, the main unanswered questions and the types of studies that should be prioritised in order to find out. We conclude by calling for a prospective Phase II study of antidepressants in depressed glioma patients, to test methodologies for a multicentre randomised controlled trial.

Entities:  

Keywords:  Depression

Mesh：

Substances：

Year:  2013        PMID： 24029545     DOI： 10.1136/jnnp-2013-306497

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  25 in total

1.  Symptom-based interventions to promote quality survivorship.

Authors:  Christina Amidei
Journal:  Neuro Oncol       Date:  2018-11-09       Impact factor: 12.300

2.  Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma.

Authors:  David O Kamson; Tiffany J Lee; Kaushik Varadarajan; Natasha L Robinette; Otto Muzik; Pulak K Chakraborty; Michael Snyder; Geoffrey R Barger; Sandeep Mittal; Csaba Juhász
Journal:  J Nucl Med       Date:  2014-09-04       Impact factor: 10.057

3.  Health-related quality of life in patients with high-grade gliomas: a quantitative longitudinal study.

Authors:  K Piil; J Jakobsen; K B Christensen; M Juhler; M Jarden
Journal:  J Neurooncol       Date:  2015-05-31       Impact factor: 4.130

Review 4.  Symptom management and quality of life in glioma patients.

Authors:  Florien W Boele; Martin Klein; Jaap C Reijneveld; Irma M Verdonck-de Leeuw; Jan J Heimans
Journal:  CNS Oncol       Date:  2014-01

Review 5.  Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.

Authors:  Terri S Armstrong; Robin Grant; Mark R Gilbert; Jong Woo Lee; Andrew D Norden
Journal:  Neuro Oncol       Date:  2015-11-02       Impact factor: 12.300

Review 6.  Neurocognitive Deficits and Neurocognitive Rehabilitation in Adult Brain Tumors.

Authors:  Julia Day; David C Gillespie; Alasdair G Rooney; Helen J Bulbeck; Karolis Zienius; Florien Boele; Robin Grant
Journal:  Curr Treat Options Neurol       Date:  2016-05       Impact factor: 3.598

7.  Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module.

Authors:  Karin Piil; Meagan Whisenant; Tito Mendoza; Terri Armstrong; Charles Cleeland; Sara Nordentoft; Loretta A Williams; Mary Jarden
Journal:  Neurooncol Pract       Date:  2020-10-19

8.  Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints.

Authors:  Pim B van der Meer; Johan A F Koekkoek; Martin J van den Bent; Linda Dirven; Martin J B Taphoorn
Journal:  J Neurooncol       Date:  2021-04-06       Impact factor: 4.130

Review 9.  Postacute Cognitive Rehabilitation for Adult Brain Tumor Patients.

Authors:  Christina Weyer-Jamora; Melissa S Brie; Tracy L Luks; Ellen M Smith; Shawn L Hervey-Jumper; Jennie W Taylor
Journal:  Neurosurgery       Date:  2021-11-18       Impact factor: 5.315

Review 10.  Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral Drawbacks.

Authors:  L Ganau; M Paris; G K Ligarotti; M Ganau
Journal:  Behav Neurol       Date:  2015-08-09       Impact factor: 3.342
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.